Indication

For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.

Medicine details

Medicine name:
estrasimod (Velsipity
SMC ID:
SMC2655
Pharmaceutical company
Pfizer Ltd
BNF chapter
Gastro-intestinal system
Submission type
Abbreviated
Publication due date:
10 June 2024